GSK halted development of an experimental drug for chronic cough, saying it was “unlikely to transform patient care” https://t.co/Tct1l6Fnbm ...

The world’s largest drugmaker is betting big on preventive medicines. Register for free to discover how its boss, Dave Ricks, is adopting conventions from Silicon Valley to do so https://t.co/WirsJ0j6X6 ...

The rise of GLP-1s has transformed the pharmaceutical company—and the industry as a whole. We explain why investors now value Lilly more like a tech giant than a drugmaker https://t.co/FeLKvk61gmIllustration: Carl Godfrey https://t.co/iZ2zKURcnK ...

GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after mixed results showed limited efficacy in late-stage clinical studies. https://t.co/zvCdQwuxRw ...

Eli Lilly has been selling pills to sick people for 150 years. But now, it wants to push treatments that stop people getting ill in the first place. Will it work? Listen to the latest episode of “Money Talks” to find out https://t.co/8Qmb1Ko5Ja ...